On May 20, 2022, Shenzhen Xianggen Biological Co., Ltd. (hereinafter referred to as “Xianggen Biologics”) and Endotarget Biologics (New Orleans, hereinafter referred to as “Endotarget”) reached a strategic cooperation agreement to jointly develop targeted protein degradation drugs (PROTAC) for the treatment of lung cancer and other tumors, and accelerate the clinical declaration, clinical trials and listing of related drugs in China and the United States. The two parties will share global knowledge and business interests.
Dr. GUANGDI WANG, founder and CEO of Endotarget and director of the RCMI Cancer Research Center in the United States, has made a major breakthrough in the field of targeted protein-degrading drugs (PROTAC). The R&D team led by Dr. GUANGDI WANG has invented two PROTAC drugs and is currently conducting preclinical studies to prepare for clinical filing in the United States.
Dr. Chenguang Yuan, co-founder and chief scientist of Xianggen Biologics, pointed out that through cooperation with Endotarget Biologics in the United States, Xianggen Bio will step into the field of targeted protein degradation drugs (PROTAC), quickly carry out preclinical research on targeted protein degradation drugs (PROTAC) for the treatment of lung cancer and other tumors, and promote the clinical declaration of related drugs in China and the United States.
The two sides agreed that the cooperation between the two sides will greatly accelerate the research and development progress of relevant drugs under development, hoping to benefit patients as soon as possible and generate the greatest social and economic benefits.
About Endotarget Biotech (www. Endotarget.com)
Endotarget is a New Orleans-based biological company focused on the development of new protein-degrading drugs (PROTAC). Endotarget focuses on high-impact targets, identifying clinically validated key nodes or biological pathways of proteins that drive the pathogenesis of multiple serious diseases, while there are currently no known treatment options or limited treatment options.